---
schema_version: "secwatch.filing_event.v1"
accession: "0001809519-24-000020"
form_type: "8-K"
ticker: "GDRX"
cik: "0001809519"
company_name: "GoodRx Holdings, Inc."
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T15:34:50.175381+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GoodRx extends $100M revolver to July 2025, COO Raj Beri departs with severance

## Summary
- Revolver maturity extended from Oct 11, 2024 to July 11, 2025; other terms unchanged.
- COO Raj Beri removed effective Feb 15, 2024; role eliminated.
- Beri to receive $1.134M cash severance (base salary + bonus) plus $375K discretionary bonus.
- Immediate vesting of 111,776 stock options at $5.94; extended exercise period for other options.
- COBRA premiums reimbursed for 12 months; Beri signed release and non-disparagement.

## SEC filing metadata
- accession: 0001809519-24-000020
- form_type: 8-K
- ticker: GDRX
- cik: 0001809519
- company_name: GoodRx Holdings, Inc.
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1809519/000180951924000020/0001809519-24-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1809519/000180951924000020/gdrx-8xkxcafifthamendmenta.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001809519-24-000020
- JSON: https://secwatch.observer/filing/0001809519-24-000020.json
- Plain text: https://secwatch.observer/filing/0001809519-24-000020.txt

## Key facts
- Executive change
  Raj Beri was removed as Chief Operating Officer at GoodRx Holdings, Inc..
  - Action: removed
  - Role: Chief Operating Officer
  source text: As previously disclosed, on January 16, 2024, the Company determined that the role currently held by Raj Beri, the Company's Chief Operating Officer, would be eliminated and the Company’s Board of Directors removed Mr. Beri as Chief Operating Officer, effective as of February 15, 2024 (the “Separation Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1809519/000180951924000020/0001809519-24-000020-index.htm
- Material Agreements
  GoodRx Holdings, Inc. entered into Fifth Amendment to First Lien Credit Agreement with Barclays Bank PLC, as administrative agent, and the lenders and other parties party thereto (effective 2024-02-20).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Barclays Bank PLC, as administrative agent, and the lenders and other parties party thereto
  - Effective: 2024-02-20
  source text: On February 20, 2024, GoodRx, Inc. (“GoodRx”), an indirect wholly-owned subsidiary of GoodRx Holdings, Inc. (the “Company”), entered into the Fifth Amendment to First Lien Credit Agreement (the “Fifth Amendment”), by and among GoodRx, as borrower, GoodRx Intermediate Holdings, LLC and the other guarantors party thereto (collectively, together with GoodRx, the “Loan Parties”), Barclays Bank PLC, as administrative agent, and the lenders and other parties party thereto, in order to amend its First Lien Credit Agreement, dated as of October 12, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), to, among other things, extend the maturity date of its $100.0 million revolving credit facility thereunder from October 11, 2024 to July 11, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1809519/000180951924000020/0001809519-24-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.